Table 2 Medication in the study groups at baseline
From: Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia
| Diet (n = 14) | Diet-plus-statin (n = 14) | P value | |
|---|---|---|---|
| Antihypertensive agents (n (%)) | |||
| Angiotensin II receptor blockers | 12 (86) | 10 (71) | 0.324 |
| Angiotensin-converting enzyme inhibitors | 2 (14) | 0 (0) | 0.241 |
| Calcium-channel blockers | 10 (71) | 8 (57) | 0.430 |
| Diuretics | 4 (29) | 3 (21) | 0.500 |
| β-blockers | 4 (29) | 3 (21) | 0.500 |
| α-blockers | 1 (7) | 0 (0) | 0.500 |
| Central sympatholytic agents | 0 (0) | 1 (7) | 0.500 |
| Glucose-lowering agents (n (%)) | |||
| Insulin and insulin analougues | 0 (0) | 0 (0) | - |
| Sulfonylureas | 0 (0) | 2 (14) | 0.241 |
| α-glucosidase inhibitors | 3 (21) | 1 (7) | 0.298 |
| Biguanides | 1 (7) | 0 (0) | 0.500 |
| Thiazolidinediones | 0 (0) | 1 (7) | 0.500 |
| Lipid-lowering agents (n (%)) | 0 (0) | 0 (0) | - |
| Antiplatelet agents (n (%)) | 2 (14) | 3 (21) | 0.500 |
